Nanoparticle formulation of ormeloxifene for pancreatic cancer.
Biomaterials. 2015 Jun;53:731-43. doi: 10.1016/j.biomaterials.2015.02.082. Epub 2015 Mar 26.
Pancreatic cancer is the fourth most prevalent cancer with about an 85% mortality rate; thus, an utmost need exists to discover new therapeutic modalities that would enhance therapy outcomes of this disease with minimal or no side effects. Ormeloxifene (ORM), a synthetic molecule…